Stellera chamaejasme and Its Main Compound Luteolin 7-O-Glucoside Alleviates Skin Lesions in Oxazolone- and 2,4-Dinitrochlorobenzene-Stimulated Murine Models of Atopic Dermatitis

Abstract

Stellera chamaejasme, also known as “Langdu”, has been traditionally used for the management of skin-related diseases such as psoriasis and skin ulcers. The aim of this study was to determine whether S. chamaejasme and its major component, luteolin 7-O-glucoside, have a preventive effect on the development of atopic dermatitis in oxazolone-treated BALB/c mice and 2,4-dinitrochlorobenzene-treated hairless mice. The epicutaneous applications of oxazolone and 2,4-dinitrochlorobenzene evoke an experimental murine atopic dermatitis-like reaction in BALB/c mouse ears and SKH-1 hairless mice. Atopic skin symptoms, including erythema (redness), pruritus (itching), exudation (weeping), excoriation (peeling), and lichenification (skin thickening), responded to treatment with S. chamaejasme aerial parts EtOH extract for 2 or 3 weeks. Histopathological examination revealed S. chamaejasme aerial parts EtOH extract significantly reduced inflammatory cell infiltration when applied to atopic dermatitis mice. In addition, luteolin 7-O-glucoside, the major active compound of the S. chamaejasme aerial parts EtOH extract, decreased serum IgE and IL-4 levels and transepidermal water loss and increased skin hydration, therefore exhibiting strong anti-atopic dermatitis activity in 2,4-dinitrochlorobenzene-induced atopic dermatitis mice. In this study, we confirmed antipruritic and antidermatitic effects of S. chamaejasme extract and its main component luteolin 7-O-glucoside in atopic dermatitis murine models. The study shows S. chamaejasme aerial parts EtOH extract and luteolin 7-O-glucoside are most likely to be potential drug candidates for atopic dermatitis treatment.

Key words

Stellera chamaejasme - Thymelaeaceae - luteolin 7-O-glucoside - atopic dermatitis - skin barrier function - interleukin 4 - immunoglobulin E

^* These authors contributed equally to this work.

• References

• 1 Spergel JM, Paller A. Atopic dermatitis and the atopic march. J Allergy Clin Immunol 2003; 112: S118-S127
• 2 Werfel T, Kapp A. Environmental and other major provocation factors in atopic dermatitis. Allergy 1998; 53: 731-739
• 3 Ong PY, Donald M. Immune dysregulation in atopic dermatitis. Curr Allergy Asthma Rep 2006; 6: 384-389
• 4 Cork MJ, Robinson DA, Vasilopoulos Y, Ferguson A, Moustafa M, MacGowan A, Duff GW, Ward SJ, Tazi-Ahnini R. New perspectives on epidermal barrier dysfunction in atopic dermatitis: gene-environment interactions. J Allergy Clin Immunol 2006; 118: 3-21
• 5 Leung DY. Atopic dermatitis: the skin as a window into the pathogenesis of chronic allergic diseases. J Allergy Clin Immunol 1995; 96: 302-319
• 6 Dold S, Wjst M, Von Mutius E, Reitmeir P, Stiepel E. Genetic risk for asthma, allergic rhinitis, and atopic dermatitis. Arch Dis Child 1992; 67: 1018-1022
• 7 Jin H, He R, Oyoshi M, Geha RS. Animal models of atopic dermatitis. J Invest Dermatol 2009; 129: 31-40
• 8 Grewe M, Bruijnzeel-Koomen CA, Schöpf E, Thepen T, Langeveld-Wildschut AG, Ruzicka T, Krutmann J. A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis. Immunol Today 1998; 19: 359-361
• 9 Spergel JM, Mizoguchi E, Oettgen H, Bhan AK, Geha RS. Roles of T_H1 and T_H2 cytokines in a murine model of allergic dermatitis. J Clin Invest 1999; 103: 1103-1111
• 10 Hamid Q, Boguniewicz M, Leung DY. Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J Clin Invest 1994; 94: 870-876
• 11 van der Heijden FL, Wierenga EA, Bos JD, Kapsenberg ML. High frequency of IL-4–producing CD4⁺ allergen-specific T lymphocytes in atopic dermatitis lesional skin. J Invest Dermatol 1991; 97: 389-394
• 12 Poulsen LK, Reimert CM, Bindslev-Jensen C, Hansen MB, Bendtzen K. Biomolecular regulation of the IgE immune response. II. In vitro IgE synthesis and spontaneous production of cytokines. Int Arch Allergy Immunol 1995; 106: 55-61
• 13 Leung DY. Atopic dermatitis: new insights and opportunities for therapeutic intervention. J Allergy Clin Immunol 2000; 105: 860-876
• 14 Zhang YH, Volis S, Sun H. Chloroplast phylogeny and phylogeography of Stellera chamaejasme on the Qinghai-Tibet Plateau and in adjacent regions. Mol Phylogenet Evol 2010; 57: 1162-1172
• 15 Xu ZH, Qin GW, Li XY, Xu RS. New biflavanones and bioactive compounds from Stellera chamaejasme L. Acta Pharm Sin 2001; 36: 669-671
• 16 Huo Q, Wang Y, Gao RY, Li WL, Du Y, Liu K. Study on antioxidation for extraction of total flavonoid in Stellera chamaejsme L. in vitro . Anim Husband Feed Sci 2010; 31: 83-84
• 17 Yang G, Chen D. Biflavanones, flavonoids, and coumarins from the roots of Stellera chamaejasme and their antiviral effect on hepatitis B virus. Chem Biodivers 2008; 5: 1419-1424
• 18 Zhang C, Zhou SS, Feng LY, Zhang DY, Lin NM, Zhang LH, Pan JP, Wang JB, Li J. In vitro anti-cancer activity of chamaejasmenin B and neochamaejasmin C isolated from the root of Stellera chamaejasme L. Acta Pharmacol Sin 2013; 34: 262-270
• 19 Kim M, Lee HJ, Randy A, Yun JH, Oh SR, Nho CW. Stellera chamaejasme and its constituents induce cutaneous wound healing and anti-inflammatory activities. Sci Rep 2017; 7: 42490
• 20 Harvey AL. Natural products in drug discovery. Drug Discov Today 2008; 13: 894-901
• 21 Reuter J, Wölfle U, Weckesser S, Schempp C. Which plant for which skin disease? Part 1: Atopic dermatitis, psoriasis, acne, condyloma and herpes simplex. J Dtsch Dermatol Ges 2010; 8: 788-796
• 22 Sheehan MP, Atherton DJ. A controlled trial of traditional Chinese medicinal plants in widespread non-exudative atopic eczema. Br J Dermatol 1992; 126: 179-184
• 23 Russell JJ. Topical tacrolimus: a new therapy for atopic dermatitis. Am Fam Physician 2002; 66: 1899-1902
• 24 Arellano FM, Wentworth CE, Arana A, Fernández C, Paul CF. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol 2007; 127: 808-816
• 25 Leung DY, Boguniewicz M, Howell MD, Nomura I, Hamid QA. New insights into atopic dermatitis. J Clin Invest 2004; 113: 651-657
• 26 Lam KS. New aspects of natural products in drug discovery. Trends Microbiol 2007; 15: 279-289
• 27 Mabona U, Van Vuuren SF. Southern African medicinal plants used to treat skin diseases. S Afr J Bot 2013; 87: 175-193
• 28 Saikia AP, Ryakala VK, Sharma P, Goswami P, Bora U. Ethnobotany of medicinal plants used by Assamese people for various skin ailments and cosmetics. J Ethnopharmacol 2006; 106: 149-157
• 29 Renz H, Jujo K, Bradley KL, Domenico J, Gelfand EW, Leung DY. Enhanced IL-4 production and IL-4 receptor expression in atopic dermatitis and their modulation by interferon-gamma. J Invest Dermatol 1992; 99: 403-408
• 30 Grassberger M, Steinhoff M, Schneider D, Luger TA. Pimecrolimus – an anti-inflammatory drug targeting the skin. Exp Dermatol 2004; 13: 721-730
• 31 Elias PM, Wood LC, Feingold KR. Epidermal pathogenesis of inflammatory dermatoses. Am J Contact Dermat 1999; 10: 119-126
• 32 Lodén M, Andersson AC, Lindberg M. Improvement in skin barrier function in patients with atopic dermatitis after treatment with a moisturizing cream (Canoderm). Br J Dermatol 1999; 140: 264-267
• 33 Aruoma OI. Nutrition and health aspects of free radicals and antioxidants. Food Chem Toxicol 1994; 32: 671-683
• 34 Kotani M, Matsumoto M, Fujita A, Higa S, Wang W, Suemura M, Kishimoto T, Tanaka T. Persimmon leaf extract and astragalin inhibit development of dermatitis and IgE elevation in NC/Nga mice. J Allergy Clin Immunol 2000; 106: 159-166
• 35 Choi MJ, Lee YM, Jin BS, Kim BH. Inhibitory effect of Luteolin liposome solution by animal model for atopic dermatitis in NC/Nga mice. Lab Anim Res 2010; 26: 47-53